Because deregulation of the Nrf2 signaling is linked to chemo-resistance in a variety of tumor types, the reversal of KEAP1 methylation or NRF2 demethylation could be a novel strategy to increase anticancer drug sensitivity. The gene discussed is KEAP1; the disease is neoplasm.